News

Filter

Current filters:

Prochymal

Osiris to sell culture-expanded MSCs business including Prochymal

11-10-2013

USA-based Osiris Therapeutics has entered into an agreement with a wholly-owned subsidiary of Mesoblast…

BiotechnologyFinancialMergers & AcquisitionsMesoblastOsiris TherapeuticsProchymal

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi

30-09-2012

As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi…

BiotechnologyChondrogenGenzymeImmunologicalsInflammatory diseasesLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Osiris gets second approval for Prochymal, in New Zealand

15-06-2012

USA-based Osiris Therapeutics (Nasdaq: OSIR) has received a second approval to market its first-in-class…

Asia-PacificBiotechnologyImmunologicalsOsiris TherapeuticsProchymalRegulation

World's first stem cell drug, Osiris' Prochymal, approved in Canada

21-05-2012

USA-based Osiris Therapeutics (Nasdaq: OSIR) has received market authorization from Health Canada to…

BiotechnologyImmunologicalsNorth AmericaOsiris TherapeuticsProchymalRegulation

Sanofi surprises Osiris by pulling out of Prochymal deal

13-02-2012

Maryland, USA-based Osiris Therapeutics (Nasdaq: OSIR) has provided an update on the status of the development…

GenzymeImmunologicalsLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Back to top